Drug Trial Radar · NCT05547464
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
497
Actual
Start
Jul 31, 2023
Primary completion
Mar 12, 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. This study includes: Part A (Phase Ib) and Part B (Phase IIa).
Conditions
- Tuberculosis
Interventions
BNT164a1Biological
Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
BNT164b1Biological
Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of solicited local reactions (pain, erythema/redness, induration/swelling) at the injection site up to 7 days after each doseTime frame: Up to 7 days after each dose
- Frequency of solicited systemic reactions (vomiting, diarrhea, headache, fatigue, muscle pain & joint pain, chills, and fever) up to 7 days after each doseTime frame: Up to 7 days after each dose
- Proportion of participants with at least one adverse event (AE) occurring from each dose to 28 days after each doseTime frame: From each dose up to 28 days after each dose
- Proportion of participants with at least one unsolicited AE occurring from Dose 1 to 28 days post-Dose 3Time frame: From Dose 1 up to 28 days post-Dose 3
- Proportion of participants with at least one serious AE or AE of special interest occurring from Dose 1 up to 168 days post-Dose 3Time frame: From Dose 1 up to 168 days post-Dose 3
- Number of unsolicited AEs from Dose 1 to 28 days post-Dose 3Time frame: From Dose 1 up to 28 days post-Dose 3
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Centro de Investigação em Saúde de Manhiça (CISM) (recruiting participants for Part B only)
Manhiça, Mozambique
Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC) (recruiting participants for Part B only)
Maputo, Mozambique
CAPRISA eThekweni Clinical Research Site
Berea, South Africa
South African Tuberculosis Vaccine Initiative SATVI
Cape Town, South Africa
Centre for Lung Infection and Immunity UCT Lung Institute
Cape Town, South Africa
Desmond Tutu Health Foundation - Masiphumele Research Office
Cape Town, South Africa
Africa Health Research Institute (AHRI)
Mtubatuba, South Africa
The Aurum Institute Tembisa CRC Clinic 4
Tembisa, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.